Celldex Therapeutics, Inc. (CLDX) vs Mineralys Therapeutics, Inc. (MLYS)

Celldex Therapeutics, Inc. and Mineralys Therapeutics, Inc. are both Biotechnology companies. Celldex Therapeutics, Inc. and Mineralys Therapeutics, Inc. are of similar size ($2.5B and $2.4B). Mineralys Therapeutics, Inc. has the higher net margin (0.00% vs −33,883.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Celldex Therapeutics, Inc. leads on 6 and Mineralys Therapeutics, Inc. on 6.

Valuation

Metric CLDX MLYS Biotechnology median
P/E n/m n/m 7.88
P/S 2,729.23 n/m 11.47
P/B 3.39 3.98 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1,923.07 n/m 10.73
Earnings yield (13.99%) (16.40%) (28.84%)
Free cash flow yield (10.00%) (6.34%) (23.03%)

Profitability

Metric CLDX MLYS Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (36,733.82%) 0.00% 0.00%
Net margin (33,883.77%) 0.00% 0.00%
Free cash flow margin (27,294.81%) 0.00% 0.00%
Return on equity (43.88%) (80.88%) (57.72%)
Return on assets (40.76%) (69.67%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLDX MLYS Biotechnology median
Revenue growth (TTM) (88.27%) — 5.64%
EPS growth (last fiscal year) (59.18%) 37.43% —
Revenue growth, 5-year CAGR (26.93%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLDX MLYS Biotechnology median
Debt to equity 0.00 0.18 0.00
Current ratio 11.82 34.46 4.73
Net debt to EBITDA 1.78 3.85 0.96

Dividend

Metric CLDX MLYS Biotechnology median
Dividend yield 2.16% — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric CLDX MLYS Biotechnology median
Market cap 2.49b 2.35b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack